NASDAQ:PXMD PaxMedica (PXMD) Stock Price, News & Analysis → Stock-Picking AI Predicts #1 Stock of 2024 (From Altimetry) (Ad) Free PXMD Stock Alerts $0.32 -0.05 (-13.62%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.26▼$0.3950-Day Range$0.32▼$0.8452-Week Range$0.26▼$29.75Volume427,649 shsAverage Volume7.07 million shsMarket Capitalization$2.37 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get PaxMedica alerts: Email Address PaxMedica MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside846.4% Upside$3.00 Price TargetShort InterestBearish9.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPaxMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePaxMedica has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.41% of the float of PaxMedica has been sold short.Short Interest Ratio / Days to CoverPaxMedica has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PaxMedica has recently increased by 376.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPaxMedica does not currently pay a dividend.Dividend GrowthPaxMedica does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PXMD. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for PaxMedica this week, compared to 1 article on an average week.Search Interest8 people have searched for PXMD on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows2 people have added PaxMedica to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PaxMedica insiders have not sold or bought any company stock.Percentage Held by Insiders57.90% of the stock of PaxMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.90% of the stock of PaxMedica is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PaxMedica is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PaxMedica is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPaxMedica has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryStock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.Click here to learn what's coming (and how to prepare). About PaxMedica Stock (NASDAQ:PXMD)PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.Read More PXMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PXMD Stock News HeadlinesMay 3, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDAApril 26, 2024 | finance.yahoo.comPaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastMay 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.April 25, 2024 | theglobeandmail.comUrgent Action: PaxMedica (NASDAQ: PXMD) Addresses Medical Crisis in MalawiApril 25, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDAApril 23, 2024 | globenewswire.comPaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101April 18, 2024 | finanznachrichten.dePaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping SicknessApril 12, 2024 | finanznachrichten.dePaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionMay 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.April 12, 2024 | markets.businessinsider.comNasdaq Down 300 Points; BlackRock Posts Upbeat EarningsApril 12, 2024 | msn.comPenny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock RalliesApril 12, 2024 | investorplace.comWhy Is PaxMedica (PXMD) Stock Up 93% Today?April 12, 2024 | investorplace.comWhy Is PaxMedica (PXMD) Stock Up 93% Today?April 11, 2024 | msn.comPaxMedica shares soar 125% post-market on drug updateApril 11, 2024 | finance.yahoo.comPaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionApril 11, 2024 | globenewswire.comPaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionApril 9, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated ConditionsMarch 23, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD PatientsMarch 13, 2024 | globenewswire.comPaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder TreatmentsMarch 6, 2024 | morningstar.comPaxMedica Inc Ordinary Shares PXMDFebruary 23, 2024 | benzinga.comPaxMedica Stock (NASDAQ:PXMD), Short Interest ReportJanuary 29, 2024 | theglobeandmail.comPaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASDJanuary 18, 2024 | finance.yahoo.comIBN Highlights PaxMedica's Video Release on Transformative ASD StudyJanuary 17, 2024 | theglobeandmail.comIBN Highlights PaxMedica’s (NASDAQ: PXMD) Video Release on Transformative ASD StudyJanuary 17, 2024 | finance.yahoo.comPaxMedica on Promising Path to Address Unmet ASD NeedsDecember 22, 2023 | finance.yahoo.comPaxMedica Files 8-K Following Nasdaq Compliance AchievementDecember 20, 2023 | finance.yahoo.comPaxMedica, Inc. (PXMD) Interactive Stock Chart - Yahoo FinanceSee More Headlines Receive PXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/05/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PXMD CUSIPN/A CIK1811623 Webwww.paxmedica.com Phone914-987-2876FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+846.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($24.4176) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-956.84% Return on Assets-388.94% Debt Debt-to-Equity RatioN/A Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.69Miscellaneous Outstanding Shares7,470,000Free Float3,143,000Market Cap$2.37 million OptionableNot Optionable Beta-0.17 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Howard J. Weisman (Age 64)CEO & Chairman Comp: $717.2kMr. Stephen Douglas Sheldon (Age 44)CFO & COO Comp: $450.85kDr. David W. Hough M.D. (Age 66)Chief Medical Officer Comp: $87.5kKey CompetitorsKazia TherapeuticsNASDAQ:KZIASonnet BioTherapeuticsNASDAQ:SONNFirst Wave BioPharmaNASDAQ:FWBIiBioNYSE:IBIOSynaptogenixNASDAQ:SNPXView All CompetitorsInsidersHoward J WeismanSold 372 sharesTotal: $174.84 ($0.47/share)Karen LarochelleSold 78 sharesTotal: $37.44 ($0.48/share)Howard J WeismanSold 162 sharesTotal: $166.86 ($1.03/share)Michael DerbySold 185 sharesTotal: $190.55 ($1.03/share)John F CoelhoSold 12 sharesTotal: $12.24 ($1.02/share)View All Insider Transactions PXMD Stock Analysis - Frequently Asked Questions Should I buy or sell PaxMedica stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PaxMedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PXMD shares. View PXMD analyst ratings or view top-rated stocks. What is PaxMedica's stock price target for 2024? 1 analysts have issued 1 year price objectives for PaxMedica's stock. Their PXMD share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 846.4% from the stock's current price. View analysts price targets for PXMD or view top-rated stocks among Wall Street analysts. How have PXMD shares performed in 2024? PaxMedica's stock was trading at $0.7570 at the beginning of the year. Since then, PXMD stock has decreased by 58.1% and is now trading at $0.3170. View the best growth stocks for 2024 here. Are investors shorting PaxMedica? PaxMedica saw a increase in short interest in April. As of April 15th, there was short interest totaling 637,700 shares, an increase of 377.0% from the March 31st total of 133,700 shares. Based on an average trading volume of 2,330,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 9.4% of the company's stock are sold short. View PaxMedica's Short Interest. When is PaxMedica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our PXMD earnings forecast. When did PaxMedica's stock split? PaxMedica shares reverse split on the morning of Tuesday, October 31st 2023. The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did PaxMedica IPO? PaxMedica (PXMD) raised $9 million in an initial public offering on Friday, August 26th 2022. The company issued 1,600,000 shares at $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO. How do I buy shares of PaxMedica? Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PXMD) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
